A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Ceritinib (Primary)
- Indications Anaplastic large cell lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 12 Dec 2016 Status changed from recruiting to completed.
- 24 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
- 24 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.